The benefit-harm ratio of PSA screening can be dramatically improved by avoiding screening, biopsy and treatment in men who are unlikely to benefit, and by referring men that do need treatment to high volume centers.
Written by:
Vickers A, Carlsson S, Laudone V, Lilja H. Are you the author?
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Urology, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden; Departments Medicine and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Reference: Eur Urol. 2014 Jan 4. pii: S0302-2838(13)01459-0.
doi: 10.1016/j.eururo.2013.12.049
PubMed Abstract
PMID: 24411991
UroToday.com Prostate Cancer Section
